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ed with recombinant ectodomains of the epitope NC16a of the BP180 antigen and carboxy-terminal domains of
BP230 antigen were used. All ELISAs were performed according to the manufacturer’s instructions. Values greater
than 8,7 U/ml were considered positive. Histopathological and DIF results were considered as the gold standard.
Global validation of the test results was established by calculating the sensitivity, specificity and both the positive and
negative predictive values.
Results. Sixty-four patients were enrolled (M:F=1:4). Ages ranged from 40 to 82 years (mean 61 years). There were
30 patients with MMP, 16 patients with OLP, 14 affected by PV, 3 lichenoid dysplasia and 1 erythema multiforme.
ELISA sensitivity and specificity was respectively 47 and 79%. PPV percentage was 67% while NPV was 63%.
Conclusions. In suspected oral MPP, both ELISA tests and histopathological + DIF have to be performed because
of ELISA low sensitivity. 
Although BP180 and BP230 are the major target antigens in patients with MMP limited to the oral cavity, they are not
the only. This aspect may explain the low sensitivity rate of ELISA in oral MMP when used as the sole diagnostic
support. 
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Objectives. Saliva has been proposed as a potential diagnostic fluid combined with proteomic analysis. The aim of
this study is to assess the proteomic salivary profile using SELDI-TOF-MS technology in patients with Oral Squa-
mous Cell Carcinoma (OSCC), grouped in relation to the TNM staging and compared with healthy subjects.
Methods. In this secondary hospital based case-control study, patients with confirmed histopathological diagnosis of
primary untreated OSCC as “cases” and healthy age- and sex-matched subjects as “controls” were consecutively
enrolled, after informed consent. Saliva (5 mL) was collected by spitting directly into a clean 15 mL conical tube,
aliquoted and stored at -80°C until use. SELDI-TOF Q10 ProteinChip system was used to screen for differentially ex-
pressed proteins in the saliva samples according to the manufacturer’s instructions (BioRad Inc). Univariate statistics
and Roc plot were used for data analysis.
Results. Twenty cases (6 M, 14 F, middle age 66.8 yy) and 20 controls (8 M, 12 F, middle age 61.9 yy) were included.
In cases, seven were early-EsOSCC (3 stage I and 4 stage II) and 13 were late-LsOSCC (7 stage III and 6 stage IV). 
Proteomic analysis showed significant statistical differences in peptide profile in control vs OSCC and in EsOSCC vs
LsOSCC samples (p<0.05). The differentiated pattern between overall OSCC and controls consisted of one peptide
peak (8940-ROC:1), between EsOSCC and controls of four peptide peaks (7096-ROC 0.93; 12712–ROC:0.89; 8086
– ROC: 0.93 and 11002 – ROC:0.93) and between LsOSCC and EsOSCC of one peptide peak (6026-ROC 0.80).
Conclusions. Although with limitation of the small sample size, this first study suggests that saliva contains pro-
teomic signatures that could serve as biomarkers for OSCC at different stages. Once validated on a large clinical co-
hort, oral fluid proteomic based on SELDI-TOF-MS technology may be extensively used as a promising new non-in-
vasive tool for early diagnosis in oral cancer patients.
References
• Jia-Yo Wu, et al. Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol. 2010;46 (4): 226-231. 
• Papale M, et al. Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-
TOF/MS): from sample collection to data analysis. Clin Chem Lab Med. 2008;46(1):89-99. 
• Shintani S, et al. Identification of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell carcinoma using the
SELDI ProteinChip platform. Int J Oral Maxillofac Surg. 2010; 39(1):68-74.
12 Annali di Stomatologia 2014; Suppl. 3 to n. 2: 1-41
